Mohamed El Tarabily, MD
Hematology & Oncology · Cheyenne, WYNPI 1467418905
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,645 of the $1,999 with a category attached, or 82.2%. It is spread thinly across 35 manufacturers, the largest accounting for just 15.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $981 and has fallen 66.8% since, to $326 in 2025.
Across 113 payments — averaging $17.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$307
- Genentech USA, Inc.$241
- Johnson & Johnson$204
- Merck$200
- Astellas Pharma US Inc$114
- AstraZeneca$96
- plus $837 from 29 others
What the payments were for
- Food & beverage$1,64582%
- Education$35518%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 12 | $307 |
| Genentech USA, Inc. | 24 | $241 |
| Johnson & Johnson | 9 | $204 |
| Merck | 12 | $200 |
| Astellas Pharma US Inc | 2 | $114 |
| AstraZeneca | 6 | $96 |
| Novartis | 4 | $74 |
| Pfizer | 5 | $65 |
| E.r. Squibb & Sons, L.L.C. | 4 | $64 |
| Seagen Inc. | 3 | $55 |
| EMD Serono, Inc. | 4 | $54 |
| GSK | 2 | $50 |
| Bayer | 2 | $46 |
| AVEO Pharmaceuticals, Inc. | 1 | $33 |
| Bristol Myers Squibb | 2 | $29 |
| Gilead(2 entities) | 2 | $27 |
| Servier Pharmaceuticals LLC | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $24 |
| Myovant Sciences Inc. | 1 | $24 |
| Tempus AI, Inc | 1 | $24 |
| Incyte Corporation | 1 | $23 |
| Coherus Oncology, Inc. | 1 | $20 |
| Lilly USA, LLC | 1 | $19 |
| Rigel Pharmaceuticals, Inc. | 1 | $18 |
| Syndax Pharmaceuticals, Inc. | 1 | $18 |
| Boehringer Ingelheim | 1 | $17 |
| Verastem, Inc. | 1 | $17 |
| Puma Biotechnology, Inc. | 1 | $16 |
| Pharmacosmos Therapeutics Inc. | 1 | $16 |
| Taiho Oncology, Inc. | 1 | $15 |
| Foundation Medicine, Inc. | 1 | $15 |
| Octapharma USA, Inc. | 1 | $15 |
| Sanofi | 1 | $14 |
| Ipsen Biopharmaceuticals, Inc | 1 | $12 |
| Clovis Oncology, Inc. | 1 | $10 |
How this compares
Too few hematology & oncology providers in Wyomingto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 31 | $494,921 |
| ImbruvicaIbrutinib | 15 | $267,377 |
| CalquenceAcalabrutinib Maleate | 11 | $169,107 |
| VenclextaVenetoclax | 15 | $148,583 |
| EliquisApixaban | 17 | $14,730 |
| Hydroxyurea | 30 | $985 |
| ValacyclovirValacyclovir Hcl | 13 | $493 |
| Anastrozole | 11 | $354 |
| Allopurinol | 35 | $280 |
| Prednisone | 34 | $243 |
| Prochlorperazine Maleate | 11 | $223 |
| Pantoprazole Sodium | 17 | $194 |
| Acyclovir | 16 | $189 |
| Gabapentin | 15 | $178 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 31 | $171 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $29 | $494,92131 claims |
| AstraZenecaCalquence | $96 | $169,10711 claims |
| PfizerEliquis | $65 | $14,73017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hematology & oncology providers in Wyomingon file to place this against a meaningful peer group, so we don't.
Other hematology & oncology in Cheyenne
- Natalie WorkmanCheyenne$6K
- Maristela BateziniCheyenne$2K
- Elizabeth HamCheyenne$23
- Elie FahedCasper$391K
- Iloabueke ChinekeCasper$11K
- Thomas ReidCody$5K
- Carletta CollinsPowell$1K
- Clinton MerrillLander$913
- Megan RattermanSheridan$334
- Gregory MarinoSheridan$292
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.